ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,0874
-0,15%
Bitcoin
66.735,68
-0,31%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. G1 Therapeutics Inc (GTHX)

  7. G1 Therapeutics Inc (GTHX) News

GTHX

G1 Therapeutics (GTHX)

G1 Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:GTHX
DatumZeitQuelleÜberschriftSymbolFirma
15/05/202422h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
15/05/202422h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
15/05/202422h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
15/05/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
01/05/202423h50GlobeNewswire Inc.G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GTHXG1 Therapeutics Inc
01/05/202412h30GlobeNewswire Inc.G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational HighlightsNASDAQ:GTHXG1 Therapeutics Inc
01/05/202412h25GlobeNewswire Inc.G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for LerociclibNASDAQ:GTHXG1 Therapeutics Inc
17/04/202415h00GlobeNewswire Inc.G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024NASDAQ:GTHXG1 Therapeutics Inc
04/04/202416h30GlobeNewswire Inc.G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:GTHXG1 Therapeutics Inc
01/04/202422h20GlobeNewswire Inc.G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GTHXG1 Therapeutics Inc
01/03/202422h20GlobeNewswire Inc.G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GTHXG1 Therapeutics Inc
28/02/202412h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GTHXG1 Therapeutics Inc
28/02/202412h30GlobeNewswire Inc.G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsNASDAQ:GTHXG1 Therapeutics Inc
27/02/202414h30GlobeNewswire Inc.G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:GTHXG1 Therapeutics Inc
15/02/202414h30GlobeNewswire Inc.G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024NASDAQ:GTHXG1 Therapeutics Inc
14/02/202400h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
12/02/202422h42Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GTHXG1 Therapeutics Inc
12/02/202422h19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GTHXG1 Therapeutics Inc
12/02/202422h05GlobeNewswire Inc.G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring CommitteeNASDAQ:GTHXG1 Therapeutics Inc
09/01/202422h19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GTHXG1 Therapeutics Inc
08/01/202412h45GlobeNewswire Inc.G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:GTHXG1 Therapeutics Inc
08/01/202412h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GTHXG1 Therapeutics Inc
08/01/202412h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
08/01/202412h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
08/01/202412h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
08/01/202412h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
08/01/202412h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
08/01/202412h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
03/01/202415h00GlobeNewswire Inc.G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:GTHXG1 Therapeutics Inc
03/01/202401h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GTHX

Kürzlich von Ihnen besucht

UNSW
SPANKETH
SpankChain
BOV
PETRT379
PETRT379 Ex:33,75
COIN
HYPEBTC
AMEX
PLMRW
PolyMet Mining
EU
ADIAP
Actiam NV
EU
ALOKW
Groupe Okwind
NASDAQ
GMST
EU
MLGEQ
Gentlemen S Equity
NASDAQ
TKLC
Tekelec
EU
ALAGP
Agripower France
TSXV
FMS
Focus Graphite
EU
ALPRG
Prologue
EU
AKE
Arkema
TSXV
UPC
EU
ADUX
Adux
EU
ALTUR
Altur Investissement
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten